Thomas Dee

 Thomas Dee has over two decades of experience leading business and financial operations for global pharma and biotechnology companies. Before joining Endsulin, he served as Chief Financial Officer of AveXis Inc, where he was responsible for bringing one of the first FDA-approved gene therapies to market. Thomas spent most of his career at Abbott Laboratories, where he held various senior leadership roles including VP of Finance Operations and VP Controller Pharmaceuticals. He holds a B.S. in accounting from Northern Illinois University and an M.B.A. from Northwestern University’s Kellogg School of Management.